ELISIO
Elisio is an IT company that provides installation and maintenance of satellite technology devices as well as online marketing services.
ELISIO
Industry:
Advertising Information Technology Satellite Communication SEO
Founded:
2003-01-01
Address:
Bratislava, Bratislava, Slovakia (Slovak Republic)
Country:
Slovakia (Slovak Republic)
Website Url:
http://www.elisio.com
Total Employee:
1+
Status:
Active
Contact:
421-903-666700
Email Addresses:
[email protected]
Technology used in webpage:
IPv6 Zoner Cloud Zoner
Similar Organizations
Don & Branco
Don & Branco is a company that specializes in branding, design, marketing strategies and web solutions & visual creation services.
MEDIA ENERGY
MEDIA ENERGY is an IT company that provides websites, e-shops, SEO, web administration and advertising service.
Readytec
Readytec is an IT company that provides management, web services, SEO, and digital marketing services.
Official Site Inspections
http://www.elisio.com
- Host name: praxidike.zarea.net
- IP address: 217.198.114.120
- Location: Brno Czechia
- Latitude: 49.2327
- Longitude: 16.6442
- Timezone: Europe/Prague
- Postal: 614 00
More informations about "Elisio"
Elicio Therapeutics - Crunchbase Company Profile
Elicio Therapeutics may be growing as evidenced by its recent financial activities and research advancements. The company has secured significant private placement financing, with announcements of $6.0 million and $7.0 million in …See details»
Elicio Therapeutics - LinkedIn
Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company advancing a pipeline of novel lymph node-targeted immunotherapies for the treatment of some of the most ...See details»
ELI-008 - Drug Targets, Indications, Patents - Synapse
BOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline …See details»
Orchestrating the immune system for precision immunity - Nature
Elicio Therapeutics Reports Third Quarter 2024 Financial
Nov 14, 2024 About Elicio Therapeutics. Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company advancing novel immunotherapies to prevent the recurrence of …See details»
How Is Your Organization Currently Leveraging Real-World Data
How Is Your Organization Currently Leveraging Real-World Data/Evidence and What Uses Do You Anticipate in the Future? PHARMA’S ALMANAC: At Elicio Therapeutics, we view real …See details»
Elicio Therapeutics Reports 2023 Financial Results and Provides ...
BOSTON, March 29, 2024 (GLOBE NEWSWIRE) — Elicio Therapeutics, Inc. (Nasdaq: ELTX,“Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a …See details»
Nature Medicine Publishes Updated Preliminary Phase 1 Data
Jan 9, 2024 Elicio undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent …See details»
Elicio Therapeutics Inc. - Nature
CAR-T cell activator, Elicio is developing ELI-004, an AMP-adjuvant with applications in a variety of indications and therapies, including as the adju-vant component of ELI-002. Finally, Elicio …See details»
Elicio Therapeutics Announces Preliminary Disease-Free Survival ...
Jun 27, 2024 Elicio Therapeutics Inc. ELI-002 7P administered as a monotherapy at the Phase 2 dose shows preliminary encouraging Disease-Free Survival data in pancreatic ductal …See details»
Elicio Therapeutics Presents Updated Translational Data
Nov 7, 2024 Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company advancing novel immunotherapies to prevent the recurrence of high-prevalence cancers, …See details»
AMP Platform Media and Resources | Elicio Therapeutics
Nov 7, 2024 BIOSPACE: Finally, Elicio Therapeutics is expected to present the first-ever data from the 7P formulation of its off-the-shelf cancer vaccine candidate, ELI-002 7P, targeting …See details»
First Patient With PDAC Receives ELI-002 7P in Phase 2 AMPLIFY …
Jan 12, 2024 The first patient with KRAS-mutated pancreatic ductal adenocarcinoma (PDAC) has been dosed with ELI-002 7P in the phase 2 AMPLIFY-7P study (NCT05726864), …See details»
Elicit: The AI Research Assistant
“A meta-analysis of 30 randomized, double-blind, placebo-controlled trials concluded that fish oil consumption can significantly reduce heart rate (Mozaffarian 2005).In particular, the effect was …See details»
Elicio Therapeutics, Inc. (ELTX) - Yahoo Finance
Find the latest Elicio Therapeutics, Inc. (ELTX) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Elicio Therapeutics Presents Updated Translational Data from ELI …
Nov 7, 2024 Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company advancing novel immunotherapies to prevent the recurrence of high-prevalence …See details»
Elisio | Nipro Canada
Description. When Nipro set out to reimagine the single use, hollow-fiber dialyzer, our goal was to evolve the new ELISIO™ into a product delivering multiple, valuable advantages.See details»
Investor Information and Resources | Elicio Therapeutics
Nov 13, 2024 Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates November 7, 2024 Elicio Therapeutics Presents Updated Translational …See details»
News | Stay Up to Date With Elicio Therapeutics
Nov 13, 2024 Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual …See details»